Evidence map›Paper›PMID 42146571›Full record

ArticlebioRxiv : the preprint server for biology2026

Dependencies in heterogeneous, lineage plastic patient-derived prostate cancer organoids revealed through integrated single-cell multiomics and CRISPR screening.

Samir Zaidi, Maren Büttner, Weiran Feng, Caitlin Baxter, D Henry Kates, Tiago Paiva Prudente, Diana Zakharova, Sanjoy Mehta, Subhiksha Nandakumar, Chen Khuan Wong and 10 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Samir ZaidiDepartment of Medicine, Yale School of Medicine, New Haven, CT 06510, USA.ORCID 0000-0003-1592-2932
Maren BüttnerCalico Life Sciences LLC, South San Francisco, CA USA.
Weiran FengCancer Epigenetics Institute, Nuclear Dynamics & Cancer Program Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
Caitlin BaxterDepartment of Medicine, Yale School of Medicine, New Haven, CT 06510, USA.
D Henry KatesHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Tiago Paiva PrudenteDepartment of Medicine, Yale School of Medicine, New Haven, CT 06510, USA.
Diana ZakharovaCancer Epigenetics Institute, Nuclear Dynamics & Cancer Program Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
Sanjoy MehtaGenome Editing and Screening Core, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Subhiksha NandakumarDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Chen Khuan WongHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Hojin LeeDepartment of Biomedical Sciences, Korea University College of Medicine, Seoul, Korea.
Pierre-Jacques HamardEpigenetic Research Innovation Lab, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Wenfei KangMolecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Jungmin ChoiDepartment of Biomedical Sciences, Korea University College of Medicine, Seoul, Korea.ORCID 0000-0002-8614-0973
Ronan ChalignéSingle Cell Analytics Innovation Lab, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Robert CohenCalico Life Sciences LLC, South San Francisco, CA USA.
Yu ChenHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-0171-3884
Ari FirestoneCalico Life Sciences LLC, South San Francisco, CA USA.
Zhenghao ChenCalico Life Sciences LLC, South San Francisco, CA USA.
Charles L SawyersCancer Epigenetics Institute, Nuclear Dynamics & Cancer Program Fox Chase Cancer Center, Philadelphia, PA 19111, USA.ORCID 0000-0003-4955-6475

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
SPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI David B. Solit · 2001 to 2026
$63.0M
Project 3: Analysis of intrinsic and extrinsic factors that promote prostate neuroendocrine differentiationP01CA265768 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Massimo Loda · 2022 to 2026
$13.4M
Role of ETS factors in specifying prostate luminal cell identity and androgen receptor dependenceR01CA193837 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2015 to 2025
$4.7M
Studies on Lineage Plasticity in Prostate CancerK08CA282978 · NCI · YALE UNIVERSITY · PI SAMIR ZAIDI · 2023 to 2026
$1.1M
NCI NIH HHS K08 CA282978NCI NIH HHS P01 CA265768NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA092629NCI NIH HHS R01 CA193837
6 · The paper itself

Abstract

Lineage plasticity and tumor heterogeneity limit the effectiveness of targeted therapies, yet the functional dependencies used to nominate therapeutic targets are often derived from homogeneous systems that fail to capture this complexity. Here, we establish a framework to resolve state-specific genetic vulnerabilities by integrating single-cell multiomics (RNA and ATAC) with pooled CRISPR-Cas9 screening across a large panel of patient-derived organoids (PDOs) from castrate-resistant prostate cancer (CRPC) and neuroendocrine prostate cancer (NEPC). We generate a single-cell multiome atlas spanning >190,000 cells across 22 PDOs, defining seven lineage states-including intermediate and plastic populations not resolved by bulk profiling-and demonstrate that these lineage programs robustly classify independent transcriptomic datasets from prostate cancer patient tumors. By systematically coupling this atlas to subtype-resolved CRISPR screens, we construct a functional dependency map linking cell state in heterogeneous 3D human tumor models. We show that intratumoral heterogeneity fundamentally reshapes the interpretation of gene essentiality, whereby gene-level depletion reflects the composite behavior of co-existing subpopulations, and identify a general principle in which resistant "limiting" populations disproportionately determine aggregate fitness effects. This framework reveals both canonical and previously unrecognized lineage-restricted dependencies within highly plastic tumor and NEPC states, including a therapeutically targetable dependency on the aryl hydrocarbon receptor (AHR) in a novel hybrid stem-like/ASCL1 population. Together, these data establish an extensive multi-dimensional prostate cancer resource, identify novel lineage-resolved biology, and provide a generalizable strategy for interpreting functional genomics in heterogeneous human tumors.

Identifiers

PMID42146571
PMCPMC13174631

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.